Activation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic Differentiation through β-Catenin.
Stem Cell Reports · 2016
Last updated 2026-05-28In a rat study, the GLP-1 drug exendin-4 (Ex-4) increased bone formation, bone mass, and bone quality while reducing fat cells in bone marrow. The drug worked by activating a receptor found in bone marrow stromal cells (not in bone-forming cells) and triggered two specific signaling pathways to promote bone cell development.
AI summary of the abstract below.
| Journal | Stem Cell Reports, 2016 |
|---|---|
| Citations | 104 |
| Relative citation ratio | 4.34 |
| NIH percentile | 91 |
| Molecules | — |
Abstract
Glucagon-like peptide 1 (GLP-1) plays an important role in regulating bone remodeling, and GLP-1 receptor agonist shows a positive relationship with osteoblast activity. However, GLP-1 receptor is not found in osteoblast, and the mechanism of GLP-1 receptor agonist on regulating bone remodeling is unclear. Here, we show that the GLP-1 receptor agonist exendin-4 (Ex-4) promoted bone formation and increased bone mass and quality in a rat unloading-induced bone loss model. These functions were accompanied by an increase in osteoblast number and serum bone formation markers, while the adipocyte number was decreased. Furthermore, GLP-1 receptor was detected in bone marrow stromal cells (BMSCs), but not in osteoblast. Activation of GLP-1 receptor by Ex-4 promoted the osteogenic differentiation and inhibited BMSC adipogenic differentiation through regulating PKA/β-catenin and PKA/PI3K/AKT/GSK3β signaling. These findings reveal that GLP-1 receptor regulates BMSC osteogenic differentiation and provide a molecular basis for therapeutic potential of GLP-1 against osteoporosis.
Verbatim abstract via PubMed 26947974 ↗